Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Results of phase IIIb BALLET trial in Spain
Clinical and Translational Oncology Nov 10, 2017
Ciruelos E, et al. - Researchers here investigated safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer. Findings revealed that in Spanish patients of the BALLET trial, the safety profile was consistent with the results obtained in the overall population of the trial, as well as in previous clinical trials.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
